# AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

> **NCT00076024** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 174 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Placebo
- **DRUG:** Docetaxel
- **DRUG:** AG-013736 (axitinib)
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00076024
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2007-01
- **Final completion:** 2008-11
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2012-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00076024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00076024, "AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00076024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*